Silence Therapeutics plc (SLN)
After hours:
| Previous close | 22.27 |
| Open | 22.23 |
| Bid | 21.58 x 200 |
| Ask | 21.84 x 100 |
| Day's range | 21.52 - 22.30 |
| 52-week range | 4.84 - 27.72 |
| Volume | |
| Avg. volume | 237,346 |
| Market cap | 1.119B |
| Beta (5Y monthly) | 1.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.45 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 57.28 |
ZacksSilence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Business WireSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
LONDON, April 08, 2024--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced additional results from the APOLLO phase 1 study of zerlasiran (SLN360) in subjects with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L were published in the Journal of the American Medical Association (JAMA), linked her
Simply Wall St.Analysts Are Upgrading Silence Therapeutics plc (NASDAQ:SLN) After Its Latest Results
It's shaping up to be a tough period for Silence Therapeutics plc ( NASDAQ:SLN ), which a week ago released some...
